Isoniazid-resistant tuberculosis in Denmark: mutations, transmission and treatment outcome
- PMID: 20347869
- DOI: 10.1016/j.jinf.2010.03.017
Isoniazid-resistant tuberculosis in Denmark: mutations, transmission and treatment outcome
Abstract
Objectives: A retrospective study on isoniazid-resistant tuberculosis (TB) was conducted in the low-burden country, Denmark (DK). The aim was to describe treatment outcome and transmission and to evaluate a mutation analysis for high- and low-level isoniazid resistance detection.
Methods: In the period 2002-2007, all isoniazid-resistant TB-cases were included. Molecular genotyping was performed by standardized IS6110 restriction fragment length polymorphism (RFLP). Identical isoniazid-resistant genotypes, indicating ongoing transmission, were identified from the national RFLP database. An analysis of rifampin (rpoB) and high- or low-level (katG, inhA) isoniazid resistance mutations was performed on subcultured strains.
Results: There were 1825 culture-confirmed cases, of which 111 (6.1%) had monoresistance or polyresistance to isoniazid. Successful short- and long-term treatment outcome was achieved in 80% and 95%, respectively. Overall, the mutation analysis predicted 94% of isoniazid resistance in 111 strains. The katG S315T1 and inhA C15T1 mutations correctly identified high- and low-level isoniazid resistance in 84% and 84% of the strains, respectively.
Conclusions: Isoniazid-resistant TB has a good prognosis in DK. High- and low- level isoniazid resistance does not affect treatment outcome of standard modified treatment. Rapid mutation detection identified the majority of isoniazid-resistant cases however the impact on treatment outcome remains to be determined.
Copyright (c) 2010 The British Infection Society. Published by Elsevier Ltd. All rights reserved.
Similar articles
-
The management of tuberculosis: epidemiology, resistance and monitoring.Dan Med Bull. 2010 Nov;57(11):B4213. Dan Med Bull. 2010. PMID: 21055374 Review.
-
Multidrug-resistant tuberculosis: treatment outcome in Denmark, 1992-2007.Scand J Infect Dis. 2010 Apr;42(4):288-93. doi: 10.3109/00365540903456282. Scand J Infect Dis. 2010. PMID: 20082573
-
Detection of isoniazid and rifampin resistance in Mycobacterium tuberculosis strains by single-strand conformation polymorphism analysis and restriction fragment length polymorphism.New Microbiol. 2003 Oct;26(4):375-81. New Microbiol. 2003. PMID: 14596348
-
Study of resistance to anti-tuberculosis drugs in five districts of Equatorial Guinea: rates, risk factors, genotyping of gene mutations and molecular epidemiology.Int J Tuberc Lung Dis. 2004 Jan;8(1):15-22. Int J Tuberc Lung Dis. 2004. PMID: 14974741
-
Tuberculosis: commentary on a reemergent killer.Science. 1992 Aug 21;257(5073):1055-64. doi: 10.1126/science.257.5073.1055. Science. 1992. PMID: 1509256 Review.
Cited by
-
Isoniazid (INH) mono-resistance and tuberculosis (TB) treatment success: analysis of European surveillance data, 2002 to 2014.Euro Surveill. 2019 Mar;24(12):1800392. doi: 10.2807/1560-7917.ES.2019.24.12.1800392. Euro Surveill. 2019. PMID: 30914081 Free PMC article.
-
Rapid detection of isoniazid resistance in Mycobacterium tuberculosis isolates by use of real-time-PCR-based melting curve analysis.J Clin Microbiol. 2014 May;52(5):1644-52. doi: 10.1128/JCM.03395-13. Epub 2014 Mar 5. J Clin Microbiol. 2014. PMID: 24599986 Free PMC article.
-
Rifampicin mono-resistant tuberculosis in France: a 2005-2010 retrospective cohort analysis.BMC Infect Dis. 2014 Jan 10;14:18. doi: 10.1186/1471-2334-14-18. BMC Infect Dis. 2014. PMID: 24410906 Free PMC article.
-
Risk factors affecting treatment outcomes for pulmonary tuberculosis in Finland 2007-2014: a national cohort study.BMC Public Health. 2020 Aug 17;20(1):1250. doi: 10.1186/s12889-020-09360-7. BMC Public Health. 2020. PMID: 32807112 Free PMC article.
-
Treatment outcomes for isoniazid-monoresistant tuberculosis in Peru, 2012-2014.PLoS One. 2018 Dec 4;13(12):e0206658. doi: 10.1371/journal.pone.0206658. eCollection 2018. PLoS One. 2018. PMID: 30513085 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical